Portal de Periódicos da CAPES

Artigo Produção Nacional Revisado por pares

BIBTEX RIS

Protective efficacy of a serogroup B meningococcal vaccine in Sao Paulo, Brazil

1992; Elsevier BV; Volume: 340; Issue: 8827 Linguagem: Inglês

10.1016/0140-6736(92)93086-3

1474-547X

José Cássio de Moraes, Maria Cláudia Corrêa Camargo, Neuma T. Hidalgo, Helena Aparecida Barbosa, Vera Lúcia Gattás, Hanna VASCONCELOS, Cláudio Tavares Sacchi, I.M. Land Gral, Bradley A. Perkins, Jay D. Wenger, Brian D. Plikaytis, Claire V. Broome,

Infective Endocarditis Diagnosis and Management

Abstract Serogroup B Neisseria meningitidis is the most common cause of epidemic meningococcal disease in developed countries. Until recently no vaccine has been available for prevention of infection with this organism. In an attempt to control epidemic serogroup B meningococcal disease in greater Sao Paulo, Brazil, during 1989 and 1990, a Cuban-produced outer-membrane-protein-based serogroup B meningococcal vaccine was given to about 2·4 million children aged from 3 months to 6 years. We have done a case-control study to estimate the efficacy of the vaccine in greater Sao Paulo. Microbiologically confirmed cases of serogroup B meningococcal disease were identified through hospital-based surveillance. Controls were matched by neighbourhood and age. Vaccination status was confirmed by inspection of vaccination cards. Between June, 1990, and June, 1991, 112 patients and 409 matched controls with confirmed vaccine status were enrolled. Estimated vaccine efficacy varied by age: 48 months or older=74% (95% Cl 16 to 92%), 24 to 47 months=47% (-72 to 84%), and less than 24 months=- 37% (<-100 to 73%). Our results suggest that the Cuban-produced vaccine may be effective for prevention of serogroup B meningococcal disease in older children and adults.